Senior Research Associate
- Email: email@example.com
- Telephone: +44 (0) 191 208 4436
- Address: University of Newcastle upon Tyne,
Northern Institute for Cancer Research,
Paul O'Gorman Building,
Newcastle upon Tyne,
Jan. 1997 - July 1999: Research Assistant, University of Glasgow.
Employed in Department of Medical Oncology.
June 1995 - Dec. 1996: Research Assistant, University of Aberdeen
Project to investigate the polymorphic enzyme dihydropyrimidine dehydrogenase in Cancer research laboratory.
Sept. 1994-June 1995: Research Assistant, University of Glasgow.
Employed in Department of Medical Oncology.
Oct. 1992-Sept. 1993: Research scientist, British Biotechnology Ltd..
Area of expertise
Measurement of cancer drugs levels in samples from cancer patients on clinical trials
Member of BACR
Method development and validation of analytical methods (HPLC and LC/MS/MS.
PCR,pyrosequencing and RFLP
Post involves method development and validation of analytical methods (HPLC and LC/MS/MS) for measurement of drug levels in biological matrixes from patients enrolled on clinical trials, pharmacokinetic analysis, liaising with medical staff and organising shipment of samples. Also use PCR, pyrosequencing and RFLP for detecting single nucleotide polymorphisms in drug metabolising enzymes. I am the Document controller for the laboratory which involves writing, reviewing and distribution of SOPs and archiving of controlled documents.
- Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. Bioanalysis 2017, 9(13), 1001-1010.
- Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV. Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. European Journal of Cancer 2017, 71, 15-24.
- Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TRJ, Anthoney A, Ranson M, Boddy AV, Plummer R. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer 2016, 68, 1-10.
- Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. European Journal of Cancer 2016, 55, 56–64.
- Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer 2016, 114(7), 723-730.
- Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NYR, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular Cancer Therapeutics 2015, 14(12), 2735-2743.
- Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, Verrill M, Boddy AV. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemotherapy and Pharmacology 2014, 74(4), 667-674.
- Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer 2011, 104(4), 593-598.
- Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EVA, Verrill MW, May FEB, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics 2011, 21(12), 808-819.